Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

BACKGROUND: Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We investigated whether crizotinib could influence heart rate (HR)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cardiooncology
Main Authors: Zhang, Zhushan, Huang, Tai-Qin, Nepliouev, Igor, Zhang, Hengtao, Barnett, Adam S., Rosenberg, Paul B., Ou, Sai-Hong I., Stiber, Jonathan A.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5310672/
https://ncbi.nlm.nih.gov/pubmed/28217366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-017-0020-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares